Comparing Two Chemotherapy Regimens for Lung Cancer
Author Information
Author(s): Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D
Primary Institution: University General Hospital of Heraklion
Hypothesis
The study aims to compare the efficacy of irinotecan plus cisplatin versus cisplatin alone as second-line chemotherapy in patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine.
Conclusion
The irinotecan/cisplatin regimen did not provide a survival benefit compared to cisplatin alone, despite a higher response rate.
Supporting Evidence
- The overall response rate was 22.5% for the irinotecan/cisplatin group compared to 7% for the cisplatin group.
- Median survival was 7.8 months for the irinotecan/cisplatin group and 8.8 months for the cisplatin group.
- Quality of life was similar between both treatment arms.
Takeaway
Doctors wanted to see if a new combination of medicines could help lung cancer patients who didn't respond to earlier treatments, but it turned out that the old medicine worked just as well.
Methodology
Patients were randomly assigned to receive either irinotecan plus cisplatin or cisplatin alone every three weeks, and their responses were evaluated.
Limitations
The study's findings may not apply to patients treated with other nonplatinum-containing regimens in the first-line setting.
Participant Demographics
Patients were aged over 18 years, with a median age of 64 years, and included both genders with stage IV disease.
Statistical Information
P-Value
0.012
Confidence Interval
95% CI: 12.8–32.2%
Statistical Significance
p=0.012
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website